177 Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With 177 Lu-PSMA-I&T.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Apr 2023
01 Apr 2023
Historique:
pubmed:
25
1
2023
medline:
4
3
2023
entrez:
24
1
2023
Statut:
ppublish
Résumé
177 Lu-rhPSMA-10.1 is a novel PSMA-targeting radiopharmaceutical that has been optimized in terms of pharmacological and pharmacokinetic properties and may be therefore advantageous in treatment of metastatic castrate-resistant prostate cancer. In this image, we present the case of an 86-year-old man with metastastic castrate-resistant prostate cancer undergoing 177 Lu-PSMA-I&T treatment. After initial partial response to radioligand therapy, another 2 treatment cycles resulted in a rising serum PSA level that could be correlated with increasingly PSMA-positive as well as a new bone lesion. Consequently, the patient was changed to 177 Lu-rhPSMA-10.1 treatment on a compassionate use basis achieving a renewed tumor response.
Identifiants
pubmed: 36692961
doi: 10.1097/RLU.0000000000004573
pii: 00003072-202304000-00013
pmc: PMC9988218
doi:
Substances chimiques
Dipeptides
0
Prostate-Specific Antigen
EC 3.4.21.77
Lutetium-177
BRH40Y9V1Q
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
337-338Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: The authors have no conflicts of interest to report. A financial grant was provided by Blue Earth Therapeutics Ltd. to support open access publication charges
Références
Chavoshi M, Mirshahvalad SA, Metser U, et al. (68)Ga-PSMA PET in prostate cancer: a systematic review and meta-analysis of the observer agreement. Eur J Nucl Med Mol Imaging . 2022;49:1021–1029.
Choyke PL, Bouchelouche K. Prostate specific membrane antigen (PSMA) imaging: the past is prologue. Transl Androl Urol . 2019;8:283–285.
von Eyben FE, Kairemo K, Paller C, et al. 177 Lu-PSMA radioligand therapy is favorable as third-line treatment of patients with metastatic castration-resistant prostate cancer. A systematic review and network meta-analysis of randomized controlled trials. Biomedicines . 2021;9:1042.
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med . 2021;385:1091–1103.
Wurzer A, Kunert JP, Fischer S, et al. Synthesis and preclinical evaluation of (177)Lu-labeled radiohybrid PSMA ligands for endoradiotherapy of prostate cancer. J Nucl Med . 2022;63:1489–1495.
Knorr K, Oh SW, Kronke M, et al. Preclinical biodistribution and dosimetry and human biodistribution comparing 18 F-rhPSMA-7 and single isomer 18 F-rhPSMA-7.3. EJNMMI Res . 2022;12.
Kroenke M, Schweiger L, Horn T, et al. Validation of 18 F-rhPSMA-7 and 18 F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer. J Nucl Med . 2022;63:1809–1814.
Feuerecker B, Chantadisai M, Allmann A, et al. Pretherapeutic comparative dosimetry of (177)Lu-rhPSMA-7.3 and (177)Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer. J Nucl Med . 2022;63:833–839.